{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:49:48Z","timestamp":1791359388484,"version":"4.3.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting presented substantial new data on antibody\u2013drug conjugates (ADCs) in lung cancer, highlighting the ongoing expansion of ADC-based strategies from later-line treatment toward first-line combination regimens. This focused narrative review summarizes and discusses the efficacy and safety findings of ADCs targeting TROP2, HER2, Nectin-4, PD-L1, c-Met, B7-H3, DLL3, SEZ6, and other emerging targets in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with particular attention to emerging ADC plus immune checkpoint inhibitor combinations in the first-line setting. Taken together, these findings highlight an expanding ADC landscape in lung cancer. However, many of the emerging strategies remain supported primarily by preliminary conference-reported or early-phase data and therefore require confirmation in mature peer-reviewed studies and adequately powered randomized clinical trials.<\/jats:p>","DOI":"10.3389\/fonc.2026.1943176","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:53:37Z","timestamp":1791356017000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging antibody\u2013drug conjugates in lung cancer: highlights from the 2026 ASCO Annual Meeting"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaolei","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Oncology, Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayuan","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Bao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanli","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchang","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8506","DOI":"10.1200\/jco.2026.44.16_suppl.8506","article-title":"Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1 - positive advanced non-small cell lung cancer (NSCLC): Results from the randomized phase 3 OptiTROP-Lung05 study","volume":"44","author":"Zhou","year":"2026","journal-title":"J Clin Oncol Abbreviation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"8523","DOI":"10.1200\/jco.2026.44.16_suppl.8523","article-title":"Dose-escalation results from a phase I study of FZ-AD004, a TROP2-directed ADC, in patients with advanced solid tumors","volume":"44","author":"Li","year":"2026","journal-title":"J Clin Oncol Abbreviation"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2026.44.16_suppl.e20500","article-title":"Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutant (HER2m) non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases (mets): Results from DESTINY-Lung05 (DL-05)","volume":"44","author":"Li","year":"2026","journal-title":"J Clin Oncol Abbreviation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1200\/jco.2026.44.16_suppl.2632","article-title":"A phase II study to evaluate the safety and efficacy of BB-1701 in combination with sintilimab in patients with HER2 expression or mutation in locally advanced\/metastatic breast cancer or NSCLC","volume":"44","author":"Xiong","year":"2026","journal-title":"J Clin Oncol Abbreviation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"8527","DOI":"10.1200\/jco.2026.44.16_suppl.8527","article-title":"SHR-A2102 in combination with adebrelimab as first-line treatment in patients with locally advanced or metastatic squamous or non-squamous non-small cell lung cancer (NSCLC): Results from a phase 1b\/2 study","volume":"44","author":"Hu","year":"2026","journal-title":"J Clin Oncol Abbreviation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"8512","DOI":"10.1200\/jco.2026.44.16_suppl.8512","article-title":"Efficacy and safety of HLX43 (anti -PD-L1 ADC) in patients with advanced non -small cell lung cancer","volume":"44","author":"Wang","year":"2026","journal-title":"J Clin Oncol Abbreviation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1200\/jco.2026.44.16_suppl.3032","article-title":"First-in-human phase 1 study of TQB6411, an EGFR\/c-Met bispecific antibody-drug conjugate (ADC), in patients with advanced solid tumors","volume":"44","author":"Ren","year":"2026","journal-title":"J Clin Oncol Abbreviation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"8525","DOI":"10.1200\/jco.2026.44.16_suppl.8525","article-title":"SHR-1826, a c-Met directed antibody-drug conjugate (ADC), in advanced solid tumors: Updates from a phase 1 study","volume":"44","author":"Sun","year":"2026","journal-title":"J Clin Oncol Abbreviation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1200\/jco.2026.44.16_suppl.3002","article-title":"First-in-human study of SYS6043, a novel B7-H3-targeting antibody-drug conjugate, in patients with advanced pan-tumor malignancies","volume":"44","author":"Zhang","year":"2026","journal-title":"J Clin Oncol Abbreviation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"8522","DOI":"10.1200\/JCO.2026.44.16_suppl.8522","article-title":"Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6) \u2500directed antibody-drug conjugate (ADC), plus pembrolizumab: Updated results from the phase 1 study (SGNB6A-001)","volume":"44","author":"Jaime","year":"2026","journal-title":"J Clin Oncol Abbreviation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"TPS8660","DOI":"10.1200\/jco.2026.44.16_suppl.tps8660","article-title":"SigVie-003: Phase 3 trial of frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab alone in non-small cell lung cancer (NSCLC) with PD-L1 TPS \u2265 50%","volume":"44","author":"Reck","year":"2026","journal-title":"J Clin Oncol Abbreviation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1200\/jco.2026.44.16_suppl.3001","article-title":"Phase I study of BL-M14D1, a novel DLL3-directed antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small-cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), and other solid tumors","volume":"44","author":"Li","year":"2026","journal-title":"J Clin Oncol Abbreviation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"8008","DOI":"10.1200\/jco.2026.44.16_suppl.8008","article-title":"ABBV-706 as monotherapy and in combination with budigalimab in patients with relapsed\/refractory (R\/R) small cell lung cancer (SCLC)","volume":"44","author":"Byers","year":"2026","journal-title":"J Clin Oncol Abbreviation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1200\/jco.2026.44.16_suppl.3011","article-title":"An open-label, first-in-human study of SKB500 in patients with locally advanced or metastatic solid tumors","volume":"44","author":"Zhang","year":"2026","journal-title":"J Clin Oncol Abbreviation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/jco.2026.44.16_suppl.3000","article-title":"DXC006, a first-in-class CD56-targeting antibody-drug conjugate, in advanced solid tumors: A first-in-human, phase I dose escalation clinical trial","volume":"44","author":"Zhao","year":"2026","journal-title":"J Clin Oncol Abbreviation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"TPS8135","DOI":"10.1016\/j.esmoop.2026.106755","article-title":"SEZanne: A phase 2 randomized, open-label, multicenter study to evaluate the optimal dose, safety, and efficacy of ABBV-706 in combination with atezolizumab (atezo) versus standard of care (SOC) in patients (pts) with previously untreated extensive-stage (ES) small cell cancer (SCLC)","volume":"44","author":"Cuppens","year":"2026","journal-title":"J Clin Oncol Abbreviations"},{"key":"B17","doi-asserted-by":"publisher","first-page":"TPS8136","DOI":"10.1200\/jco.2026.44.16_suppl.tps8136","article-title":"A randomized, open-label, phase 3 study of ZL-1310, a DLL3 antibody-drug conjugate (ADC), compared to investigator\u2019s choice therapy in participants with relapsed small cell lung cancer (DLLEVATE)","volume":"44","author":"Dowlati","year":"2026","journal-title":"J Clin Oncol Abbreviation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"TPS8663","DOI":"10.1200\/jco.2026.44.16_suppl.tps8663","article-title":"Telisotuzumab adizutecan (Temab-A) plus osimertinib (osi) as 1L treatment for unresectable\/metastatic NSCLC","volume":"44","author":"Goto","year":"2026","journal-title":"J Clin Oncol Abbreviation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"TPS8661","DOI":"10.1200\/jco.2026.44.16_suppl.tps8661","article-title":"AndroMETa-Lung-713: A phase 2\/3 study of telisotuzumab adizutecan (ABBV-400, Temab-A) vs standard of care (SOC) in patients with epidermal growth factor receptor (EGFR) \u2013 mutated non \u2013 small cell lung cancer (NSCLC)","volume":"44","author":"Rock","year":"2026","journal-title":"J Clin Oncol Abbreviation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"TPS3155","DOI":"10.1200\/jco.2026.44.16_suppl.tps3155","article-title":"A phase 1\/2, first-in-human, open-label, dose-escalation, and expansion study of TAK-188, a novel antibody-drug conjugate (ADC) targeting CCR8+ regulatory T cells, in adult patients with locally advanced or metastatic solid tumors","volume":"44","author":"Olszanski","year":"2026","journal-title":"J Clin Oncol Abbreviation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"TPS3159","DOI":"10.1200\/jco.2026.44.16_suppl.tps3159","article-title":"A phase 1, first-in-human study of DS3610, a stimulator of interferon genes (STING) agonist antibody-drug conjugate (ADC), in patients with advanced\/metastatic solid tumors","volume":"44","author":"Koganemaru","year":"2026","journal-title":"J Clin Oncol Abbreviation"},{"key":"B22","doi-asserted-by":"publisher","first-page":"TPS3160","DOI":"10.1200\/jco.2026.44.16_suppl.tps3160","article-title":"BNT326-01: A Phase 1b\/2 trial of BNT326\/YL202 (HER3 ADC) as monotherapy and in combination with pumitamig (anti-PD-L1 \u00d7 VEGF bsAb) in patients with advanced solid tumors","volume":"44","author":"Fu","year":"2026","journal-title":"J Clin Oncol Abbreviation"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1943176\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:53:37Z","timestamp":1791356017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1943176\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":22,"alternative-id":["10.3389\/fonc.2026.1943176"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1943176","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"article-number":"1943176"}}